Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to …
C Krieckaert, B Hernández-Breijo, JE Gehin… - RMD open, 2022 - rmdopen.bmj.com
The objectives of this review were to collect and summarise evidence on therapeutic drug
monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal …
monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal …
Tapering of biological treatment in autoinflammatory diseases: a scoping review
T Welzel, L Oefelein, M Twilt, M Pfister… - Pediatric …, 2022 - Springer
Background Biological treatment and treat-to-target approaches guide the achievement of
inactive disease and clinical remission in Autoinflammatory Diseases (AID). However, there …
inactive disease and clinical remission in Autoinflammatory Diseases (AID). However, there …
A phase I clinical study comparing the tolerance, immunogenicity, and pharmacokinetics of proposed biosimilar BAT1806 and reference tocilizumab in healthy …
H Zhang, H Wang, H Wei, H Chen, J Liu, C Li… - Frontiers in …, 2021 - frontiersin.org
Objective: The study aimed to explore the bioequivalence of a proposed biosimilar BAT1806
to its reference products marketed in the EU and US (RoActemra-EU and Actemra-US) …
to its reference products marketed in the EU and US (RoActemra-EU and Actemra-US) …
A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma …
Background Tocilizumab prevents the clinical worsening of chronic active antibody-
mediated rejection (CAAMR) in kidney transplant recipients. Following a global shortage of …
mediated rejection (CAAMR) in kidney transplant recipients. Following a global shortage of …
A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy …
H Zhang, X Li, J Liu, C Li, M Wu, X Zhu, J Sun… - Annals of …, 2021 - Taylor & Francis
Purpose QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We
investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S biosimilar in …
investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S biosimilar in …
Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication
F Hooijberg, Z Layegh, M Leeuw, L Boekel… - Therapeutic Drug …, 2024 - journals.lww.com
Background: Tocilizumab in the treatment of rheumatoid arthritis (RA) is a potential
candidate for concentration-guided tapering because the standard dose of tocilizumab …
candidate for concentration-guided tapering because the standard dose of tocilizumab …